

# Didier Ducloux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9020056/publications.pdf>

Version: 2024-02-01

110  
papers

3,758  
citations

117625

34  
h-index

138484

58  
g-index

116  
all docs

116  
docs citations

116  
times ranked

4184  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants. <i>Journal of Chemotherapy</i> , 2022, 34, 199-202.	1.5	2
2	REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme. <i>Kidney International</i> , 2022, 101, 645-646.	5.2	15
3	Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach. <i>Journal of Personalized Medicine</i> , 2022, 12, 116.	2.5	9
4	Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients. <i>Journal of Infection</i> , 2022, 84, e34-e35.	3.3	6
5	Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.	0.7	11
6	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	4.7	8
7	Pretransplant coronary artery disease screening is still valid. <i>Kidney International</i> , 2021, 99, 772.	5.2	1
8	Genetic determinant of thymopoiesis and clinical outcomes in renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2345-2347.	0.7	0
9	Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.	1.6	3
10	New Insights on End-Stage Renal Disease and Healthy Individual Gut Bacterial Translocation: Different Carbon Composition of Lipopolysaccharides and Different Impact on Monocyte Inflammatory Response. <i>Frontiers in Immunology</i> , 2021, 12, 658404.	4.8	5
11	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. <i>Transplantation</i> , 2021, 105, 1858-1868.	1.0	3
12	Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2270-2272.	2.9	12
13	Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune status. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2266-2267.	2.9	10
14	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.8	8
15	Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. <i>Kidney International</i> , 2021, 100, 702-704.	5.2	99
16	End-Stage Renal Disease-Related Accelerated Immune Senescence: Is Rejuvenation of the Immune System a Therapeutic Goal?. <i>Frontiers in Medicine</i> , 2021, 8, 720402.	2.6	8
17	Should vaccination against COVID-19 be mandated in patients on the transplant waiting list?. <i>Kidney International</i> , 2021, 100, 939-940.	5.2	1
18	Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 624-632.	0.7	73

#	ARTICLE	IF	CITATIONS
19	Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 978-987.	4.4	6
20	Pre-transplant Thymic Function Predicts Is Associated With Patient Death After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 1653.	4.8	10
21	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	5.2	213
22	Portable low-flow daily home haemodialysis monitor to cope with the COVID-19 outbreak. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2200-2202.	0.7	0
23	Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. <i>Kidney International Reports</i> , 2020, 5, 2195-2201.	0.8	4
24	Organ Transplantation in Hereditary Fibrinogen A $\beta$ 1-Chain Amyloidosis: A Case Series of French Patients. <i>American Journal of Kidney Diseases</i> , 2020, 76, 384-391.	1.9	5
25	IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). <i>Kidney International</i> , 2020, 98, 1568-1577.	5.2	85
26	A simple score to predict early death after kidney transplantation. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13312.	3.4	0
27	Immune phenotype predicts new onset diabetes after kidney transplantation. <i>Human Immunology</i> , 2019, 80, 937-942.	2.4	5
28	End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1630.	4.8	24
29	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 298.	2.4	3
30	Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF). <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 858-863.	0.7	13
31	Incidence, Predictors, and Impact on Six-Month Mortality of Three Different Definitions of Contrast-Induced Acute Kidney Injury After Coronary Angiography. <i>American Journal of Cardiology</i> , 2018, 121, 818-824.	1.6	19
32	ESRD-associated immune phenotype depends on dialysis modality and iron status: clinical implications. <i>Immunity and Ageing</i> , 2018, 15, 16.	4.2	47
33	Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw368.	0.7	34
34	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. <i>Transplant International</i> , 2017, 30, 256-265.	1.6	30
35	Late Persistent Positive EBV Viral Load and Risk of Solid Cancer in Kidney Transplant Patients. <i>Transplantation</i> , 2017, 101, 1473-1478.	1.0	7
36	Antithymocyte globulins in renal transplantation—from lymphocyte depletion to lymphocyte activation: The doubled-edged sword. <i>Transplantation Reviews</i> , 2017, 31, 180-187.	2.9	8

#	ARTICLE	IF	CITATIONS
37	Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins. <i>Transplant Immunology</i> , 2017, 45, 48-52.	1.2	6
38	Posttransplant Immune Activation. <i>Cell Transplantation</i> , 2017, 26, 1601-1609.	2.5	11
39	Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. <i>PLoS ONE</i> , 2017, 12, e0179406.	2.5	8
40	One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation. <i>Transplantation</i> , 2016, 100, 391-399.	1.0	157
41	Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients. <i>Kidney International</i> , 2016, 89, 1136-1143.	5.2	31
42	Pretransplant end-stage renal disease-related immune risk profile in kidney transplant recipients predicts posttransplant infections. <i>Transplant Infectious Disease</i> , 2016, 18, 415-422.	1.7	39
43	Alloimmune Responses and Atherosclerotic Disease After Kidney Transplantation. <i>Transplantation</i> , 2015, 99, 220-225.	1.0	8
44	Serum immunoglobulin G levels and peritonitis in peritoneal dialysis patients. <i>Journal of Nephrology</i> , 2015, 28, 511-515.	2.0	2
45	Regulatory T cells and cancer: an undesired tolerance. <i>Kidney International</i> , 2014, 86, 16-18.	5.2	5
46	Peritoneal Dialysis Reduces the Number of Hospitalization Days in Heart Failure Patients Refractory to Diuretics. <i>Peritoneal Dialysis International</i> , 2014, 34, 100-108.	2.3	74
47	Polyclonal Antithymocyte Globulin and Cardiovascular Disease in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1349-1356.	6.1	25
48	The Role of CMV and EBV Renal Allograft Loss. <i>American Journal of Transplantation</i> , 2013, 13, 2230-2230.	4.7	0
49	CMV and Cardiovascular Disease: Reply. <i>Journal of Infectious Diseases</i> , 2013, 208, 1349-1350.	4.0	0
50	Cytomegalovirus Exposure and Cardiovascular Disease in Kidney Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2013, 207, 1569-1575.	4.0	63
51	Influence of Fractalkine Receptor Gene Polymorphisms V249I-T280M on Cancer Occurrence After Renal Transplantation. <i>Transplantation</i> , 2013, 95, 728-732.	1.0	10
52	CD4 T Lymphopenia, Thymic Function, Homeostatic Proliferation and Late Complications Associated with Kidney Transplantation. , 2013, , .		1
53	Cytomegalovirus exposure, immune exhaustion and cancer occurrence in renal transplant recipients. <i>Transplant International</i> , 2012, 25, 948-955.	1.6	23
54	A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. <i>Clinical Nephrology</i> , 2012, 77, 126-136.	0.7	19

#	ARTICLE	IF	CITATIONS
55	The COX-2 gene promoter polymorphism -765 delays CD4 T-cell reconstitution after lymphocyte depletion with antithymocyte globulins. <i>Human Immunology</i> , 2011, 72, 1060-1063.	2.4	4
56	Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. <i>Transplant Immunology</i> , 2011, 25, 56-60.	1.2	26
57	The Interleukin-6 Gene Promoter Polymorphism -174 and Atherosclerotic Events in Overweight Transplanted Patients. <i>Journal of Transplantation</i> , 2011, 2011, 1-6.	0.5	9
58	Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation. <i>Clinical Transplantation</i> , 2011, 25, 794-799.	1.6	28
59	Potential influence of dialysis modality on post-transplantation diabetes mellitus risk. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2063-2063.	0.7	0
60	Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction. <i>Transplant International</i> , 2010, 23, 313-324.	1.6	17
61	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2628-2640.	3.0	141
62	Prolonged CD4 T Cell Lymphopenia Increases Morbidity and Mortality after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 868-875.	6.1	87
63	Significant Increase in 1-Year Posttransplant Renal Arterial Index Predicts Graft Loss. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1867-1872.	4.5	16
64	Influence of Cyclooxygenase-2 (COX-2) Gene Promoter Polymorphism at Position -765 on Skin Cancer after Renal Transplantation. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2134-2136.	0.7	5
65	The Case of a female with hyponatremia. <i>Kidney International</i> , 2009, 76, 351-352.	5.2	4
66	Influence of Cyclooxygenase-2 (COX-2) Gene Promoter Polymorphism -765 on Graft Loss After Renal Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 2752-2757.	4.7	13
67	G-765C COX-2 Gene Promoter Polymorphism and Risk of Atherosclerosis After Kidney Transplantation. <i>Transplantation</i> , 2009, 88, 851-852.	1.0	2
68	Lymphocyte Subsets in Renal Transplant Recipients with de novo Genitourinary Malignancies. <i>Urologia Internationalis</i> , 2008, 80, 257-263.	1.3	6
69	Pretransplant Serum Vitamin D Levels and Risk of Cancer After Renal Transplantation. <i>Transplantation</i> , 2008, 85, 1755-1759.	1.0	45
70	Impact of renal dysfunction and glucometabolic status on one month mortality after acute myocardial infarction. <i>Acute Cardiac Care</i> , 2007, 9, 34-42.	0.2	5
71	Metabolic Syndrome and Atherosclerotic Events in Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1577-1581.	1.0	66
72	Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant. <i>Clinical Transplantation</i> , 2007, 21, 295-300.	1.6	9

#	ARTICLE	IF	CITATIONS
73	BK virus-associated urologic complications. <i>Pediatric Transplantation</i> , 2007, 11, 821-822.	1.0	2
74	Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. <i>American Heart Journal</i> , 2006, 151, 661-667.	2.7	49
75	No Evidence of Association between NOD2/CARD15 Gene Polymorphism and Atherosclerotic Events after Renal Transplantation. <i>Transplantation</i> , 2006, 81, 1212-1215.	1.0	6
76	Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection*. <i>Transplant International</i> , 2006, 19, 759-768.	1.6	63
77	Impact of malnutrition-inflammatory on the association between homocysteine and mortality. <i>Kidney International</i> , 2006, 69, 331-335.	5.2	57
78	IL-6 Promoter Polymorphism -174 Is Associated with New-Onset Diabetes after Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2333-2340.	6.1	59
79	Cytomegalovirus and Thromboembolism in Renal Transplantation. <i>Transplantation</i> , 2005, 79, 248-249.	1.0	3
80	Posttransplant Diabetes Mellitus and Atherosclerotic Events in Renal Transplant Recipients: A Prospective Study. <i>Transplantation</i> , 2005, 79, 438-443.	1.0	82
81	Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. <i>Kidney International</i> , 2005, 67, 2454-2461.	5.2	150
82	One-Year Posttransplant Weight Gain is a Risk Factor for Graft Loss. <i>American Journal of Transplantation</i> , 2005, 5, 2922-2928.	4.7	113
83	Polyomavirus in a Lung Transplant Patient. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 976-976.	2.5	0
84	Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2005, 90, 569-70.	3.5	7
85	Acquired hypercoagulable state in renal transplant recipients. <i>Thrombosis and Haemostasis</i> , 2004, 91, 646-654.	3.4	54
86	Predicting coronary heart disease in renal transplant recipients: A prospective study. <i>Kidney International</i> , 2004, 66, 441-447.	5.2	149
87	Six-month cardiovascular changes in cyclosporine-treated recipients of corneal grafts: serial baroreflex responses. <i>Transplant International</i> , 2004, 17, 325-33.	1.6	3
88	Cytomegalovirus-associated venous thromboembolism in renal transplant recipients: A report of 7 cases. <i>Transplantation</i> , 2004, 77, 597-599.	1.0	37
89	NEW-ONSET DIABETES AFTER TRANSPLANTATION: ONE POINT TO CONSIDER. <i>Transplantation</i> , 2004, 77, 1130-1131.	1.0	1
90	LONG-TERM TOXICITY OF ANTITHYMOCYTE GLOBULIN INDUCTION MAY VARY WITH CHOICE OF AGENT: A SINGLE-CENTER RETROSPECTIVE STUDY. <i>Transplantation</i> , 2004, 77, 1029-1033.	1.0	63

#	ARTICLE	IF	CITATIONS
91	Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients. <i>Kidney International</i> , 2003, 64, 1065-1070.	5.2	30
92	CD4 Cell Lymphopenia and Atherosclerosis in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 767-772.	6.1	77
93	Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 865-870.	0.7	30
94	Homocysteine, nutritional status and insulin in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1674-1677.	0.7	10
95	Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. <i>Transplant International</i> , 2002, 15, 387-392.	1.6	40
96	Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. <i>Transplant International</i> , 2002, 15, 393-396.	1.6	51
97	C-reactive protein and cardiovascular disease in peritoneal dialysis patients. <i>Kidney International</i> , 2002, 62, 1417-1422.	5.2	131
98	Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipients. <i>Transplantation</i> , 2002, 73, 663-665.	1.0	19
99	Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. <i>Transplant International</i> , 2002, 15, 387-92.	1.6	7
100	Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. <i>Transplant International</i> , 2002, 15, 393-6.	1.6	29
101	Use of pentoxifylline in membranous nephropathy. <i>Lancet, The</i> , 2001, 357, 1672-1673.	13.7	58
102	Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. <i>Clinical Transplantation</i> , 2000, 14, 561-566.	1.6	24
103	Serum Total Homocysteine and Cardiovascular Disease Occurrence in Chronic, Stable Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 134-137.	6.1	178
104	PREVALENCE AND CLINICAL SIGNIFICANCE OF ANTIPHOSPHOLIPID ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, 90-93.	1.0	65
105	Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. <i>Transplant International</i> , 1998, 11, 312-315.	1.6	7
106	CD4 LYMPHOCYTOPENIA AS A RISK FACTOR FOR SKIN CANCERS IN RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1998, 65, 1270-1272.	1.0	112
107	RECURRENCE OF HEMOLYTIC-UREMIC SYNDROME IN RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1998, 65, 1405-1407.	1.0	66
108	MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS WITH CYCLOSPORINE-ASSOCIATED NEPHROTOXICITY. <i>Transplantation</i> , 1998, 65, 1504-1506.	1.0	76

#	ARTICLE	IF	CITATIONS
109	MYCOPHENOLATE MOFETIL-INDUCED VILLOUS ATROPHY. Transplantation, 1998, 66, 1115-1116.	1.0	80
110	Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation, 1998, 65, S149.	1.0	0